Future Oncol. 2015;11(7):1023-1026. Tumor-negative breast cancers misclassified as HER2 negative by IHC (0 or 1+) could therefore be reclassified by FISH, with a remarkable impact on medical ...

in order to evaluate discordant cases between IHC and FISH and to enable patients misclassified as HER2-negative to receive an appropriate anti-HER2 therapy, with the consequential prognostic ...

HER2-0 expression was defined as no membrane staining (IHC score 0), while HER2-low expression was defined as weak and incomplete membrane immunostaining with no HER2 gene amplification detected by ...

for trastuzumab deruxtecan for the treatment of adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-low (immunohistochemistry [IHC] 1+ or IHC 2+/in situ ...

而目前获批用于检测 HER2 扩增和过表达的手段有 IHC、FISH 和 NGS。FISH 检测为 HER2 扩增检测的金标准，对于 IHC 2+ 者可用 FISH 检测复核；NGS 检测 HER2 扩增的准确性易受肿瘤细胞含量、肿瘤内异质性、核酸质量及生物信息分析的影响，且判读标准尚无共识，暂不作为 ...

Daiichi Sankyo announced that it has submitted a supplemental New Drug Application (sNDA) to Japan’s Ministry of Health, Labour and Welfare (MHLW) for Enhertu (trastuzumab deruxtecan) for the ...

NEW YORK – The recent expansion of AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) as a treatment for low HER2-expressing metastatic breast cancer has upended established testing and ...